Climb Bio, INC. (CLYM) SEC Filings — 2024
27 SEC filings for Climb Bio, INC. (CLYM) in 2024.
Filings
- Climb Bio, INC. SC 13G/A Filing — SC 13G/A · Nov 14, 2024
- Climb Bio, Inc. Files Q3 2024 10-Q — 10-Q · Nov 12, 2024
- Climb Bio, Inc. (fka Eliem Therapeutics) Files 8-K — 8-K · Oct 15, 2024
- Climb Bio, Inc. Files 8-K with Corporate Updates — 8-K · Oct 2, 2024
- Eliem Therapeutics Reports Director Changes — 8-K · Aug 27, 2024
- Eliem Therapeutics Names New Directors, Updates Exec Pay — 8-K · Aug 26, 2024
- AI ETI LLC Amends Eliem Therapeutics Stake — SC 13D/A · Aug 16, 2024
- Eliem Therapeutics, INC. SC 13G/A Filing — SC 13G/A · Aug 14, 2024
- Eliem Therapeutics Files 8-K on Operations — 8-K · Aug 14, 2024
- Eliem Therapeutics, INC. SC 13G Filing — SC 13G · Jul 2, 2024
- RA Capital Amends Eliem Therapeutics Stake Filing — SC 13D/A · Jul 1, 2024
- Santhera Acquires Eliem Therapeutics for $10.5M — 8-K · Jun 27, 2024
- Eliem Therapeutics Files 8-K for Security Holder Votes and Other Events — 8-K · Jun 26, 2024
- Eliem Therapeutics Files Proxy Statement Supplement — DEFA14A · Jun 14, 2024
- Eliem Therapeutics Appoints New CMO, Directors — 8-K · Jun 12, 2024
- RA Capital Amends Eliem Therapeutics Stake — SC 13D/A · Jun 6, 2024
- AI ETI LLC Amends Eliem Therapeutics Stake — SC 13D/A · May 17, 2024
- RA Capital Management Amends Eliem Therapeutics Stake — SC 13D/A · May 17, 2024
- Eliem Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024
- Eliem Therapeutics, INC. SC 13G Filing — SC 13G · May 7, 2024
- Eliem Therapeutics Files 10-K/A Amendment No. 1 for Fiscal Year Ended Dec 31, 2023 — 10-K/A · Apr 29, 2024
- RA Capital Adjusts Eliem Therapeutics Stake — SC 13D/A · Apr 12, 2024
- Eliem Therapeutics Announces Officer Departure, Equity Sales — 8-K · Apr 11, 2024
- Eliem Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024
- Eliem Therapeutics Relocates Principal Executive Offices — 8-K · Mar 19, 2024
- RA Capital Adjusts Eliem Therapeutics Stake — SC 13D/A · Mar 18, 2024
- BML Investment Partners Amends Eliem Therapeutics Stake — SC 13G/A · Feb 7, 2024